CNS Pharmaceuticals, Inc. (CNSP)
| Market Cap | 5.49M +79.1% |
| Revenue (ttm) | n/a |
| Net Income | -15.85M |
| EPS | -35.75 |
| Shares Out | 811.45K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 220,972 |
| Open | 6.94 |
| Previous Close | 7.29 |
| Day's Range | 5.80 - 7.60 |
| 52-Week Range | 1.90 - 34.80 |
| Beta | 0.54 |
| Analysts | Strong Buy |
| Price Target | 20.00 (+195.86%) |
| Earnings Date | May 22, 2026 |
About CNSP
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of g... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for CNSP stock is "Strong Buy" and the 12-month stock price target is $20.0.
News
3 Penny Stocks to Watch Now, 5/5/26
CNS Pharmaceuticals ($CNSP), Elong Power Holding ($ELPW), and Skycorp Solar Group ($PN) are the three penny stocks to watch on May 5, according to TipRanks’ Penny Stock Screener tool. Penny…
Why Is CNS Pharmaceuticals Stock (CNSP) Up Today?
CNS Pharmaceuticals stock underwent a massive rally alongside a $22.5 million private placement.
CNS Pharmaceuticals prices 650,000 shares at $2.30 in private placement
CNS Pharmaceuticals (CNSP) entered into securities purchase agreements for a private placement financing that is expected to result in gross proceeds of approximately $22.5M to the Company, before pla...
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
The private placement includes participation from several leading healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners Proceeds expected to e...
CNS Pharmaceuticals launches new corporate growth strategy
CNS Pharmaceuticals (CNSP) has launched a new corporate growth strategy designed to build a high-value pipeline in neurology and oncology. The strategy is being led by the newly formed executive…
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing markets Strategic trans...
CNS Pharmaceuticals appoints Lynne Kelley as CMO
CNS Pharmaceuticals (CNSP) announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer. Prior to joining CNS Pharmaceuticals, Dr. Kelley served as CMO at multiple public and private…
CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team
Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNS Newly formed executive team is committed to execution and co...
CNS Pharmaceuticals appoints Steven O’Loughlin as CFO, Dylan Wenke as CBO
CNS Pharmaceuticals (CNSP) announced the Company’s recently appointed President and CEO, Rami Levin, in close alignment with the Board of Directors, has recruited key members to his new executive team...
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation
New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional Expertise to Support Company Growth and Value Creation HOUSTON, TX / ACCES...
CNS Pharmaceuticals says priority ‘is to transform’ how company operates
CNS Pharmaceuticals (CNSP) issued a Letter to Shareholders from its newly appointed President and CEO Rami Levin, which read in part, “I am honored to write to you for the…
CNS Pharmaceuticals Issues Letter to Shareholders
Newly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CNS Pharmaceuticals Strategic Focus, Pipeline Optimization and Formalizing Roadmap for Near and Long-T...
CNS Pharmaceuticals Inc trading resumes
09:44 EST CNS Pharmaceuticals (CNSP) Inc trading resumes
CNS Pharmaceuticals Inc trading halted, volatility trading pause
09:32 EST CNS Pharmaceuticals (CNSP) Inc trading halted, volatility trading pause
CNS Pharmaceuticals CEO John Climaco steps down, Rami Levin succeeds
CNS Pharmaceuticals (CNSP) announced John Climaco has stepped down as CEO of CNS Pharmaceuticals and Rami Levin, MBA, has been appointed as President & CEO. Levin will join CNS effective…
CNS Pharmaceuticals Announces CEO Transition
Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), ...
CNS Pharmaceuticals reports Q3 EPS ($5.76) vs. ($153.20) last year
“As we head into the final quarter of the year, our mission remains centered on delivering meaningful developments for patients battling brain and CNS cancers. We continue to build momentum…
CNS Pharmaceuticals sees cash runway into 2H26
As of September 30, 2025, the Company had cash of approximately $9.9 million. While trial costs are difficult to estimate and the Company does not yet have firm estimates as…
CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Cash expected to fund operations into the second half of 2026 Company focused on advancing next-generation anti-cancer therapies derived from well-established drug classes, now engineered to cross the...
CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting
HOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments fo...
CNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmap
As previously reported, Maxim upgraded CNS Pharmaceuticals (CNSP) to Buy from Hold with a $20 price target The company has pivoted to its oncology asset TPI-287, a blood brain barrier…
CNS Pharmaceuticals upgraded to Buy from Hold at Maxim
Maxim upgraded CNS Pharmaceuticals (CNSP) to Buy from Hold with a $20 price target
CNS Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Focused on neuro-oncology, the company advances two blood-brain barrier-penetrant drugs for glioblastoma, with TPI 287 showing strong survival benefits and Berubicin offering a new third-line option. Financial stability and a global clinical network support rapid development.
CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments fo...
CNS Pharmaceuticals reports Q2 EPS ($6.42) vs. ($4,049.20) last year
“Every decision we make is grounded in our science and driven by a sense of urgency and responsibility to the patients and families counting on us for better outcomes. We…